1/5
03:57 pm
vtvt
An Alzheimer's Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here? [Yahoo! Finance]
Low
Report
An Alzheimer's Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here? [Yahoo! Finance]
1/5
08:02 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at TD Cowen. They set a "buy" rating and a $67.00 price target on the stock.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at TD Cowen. They set a "buy" rating and a $67.00 price target on the stock.
1/5
07:03 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
Medium
Report
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
12/30
04:16 pm
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/27
01:05 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at
Wall Street Z
Low
Report
vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at
Wall Street Z
12/24
07:01 pm
vtvt
vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
Low
Report
vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
12/23
04:14 pm
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/19
07:04 pm
vtvt
We're Interested To See How vTv Therapeutics (NASDAQ:VTVT) Uses Its Cash Hoard To Grow [Yahoo! Finance]
Low
Report
We're Interested To See How vTv Therapeutics (NASDAQ:VTVT) Uses Its Cash Hoard To Grow [Yahoo! Finance]
12/19
09:09 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/18
04:36 pm
vtvt
vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health [Yahoo! Finance]
Low
Report
vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health [Yahoo! Finance]
12/18
04:05 pm
vtvt
vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
Medium
Report
vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
12/16
04:42 pm
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/10
04:12 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/2
03:47 pm
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
01:59 pm
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/20
06:03 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
11/19
08:07 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at BTIG Research. They set a "buy" rating and a $40.00 price target on the stock.
Medium
Report
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at BTIG Research. They set a "buy" rating and a $40.00 price target on the stock.
11/18
01:23 pm
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/7
01:15 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
vTv Therapeutics (NASDAQ:VTVT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
06:34 pm
vtvt
vTv Therapeutics GAAP EPS of -$1.08 misses by $0.11 [Seeking Alpha]
Medium
Report
vTv Therapeutics GAAP EPS of -$1.08 misses by $0.11 [Seeking Alpha]
11/6
04:15 pm
vtvt
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Low
Report
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update